The firm amended the terms of a deal with Pfizer and submitted results from the BREAKWATER trial of Braftovi, Erbitux, and chemo against chemo alone.

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Results of progression-free survival (PFS) and updated interim overall survival (OS) analyses from the phase 3 BREAKWATER study show that the combination of dual-targeted therapies encorafenib and ...

CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

Serial circulating tumor DNA analysis can demonstrate rapid clonal dynamics that evolve during response and resistance to both standard chemotherapy and targeted therapy of BRAF-mutant colon cancer ...

There’s been an exciting new development for some patients with metastatic colorectal cancer: a groundbreaking FDA approval has introduced a new treatment option specifically designed for those with ...

Please provide your email address to receive an email when new articles are posted on . In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, ...

BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal ...

Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...